ZYNE Insider Trading Activity and SEC Form 4 Filings
ZYNE insider trading summary
No open-market insider purchases or sales of Zynerba Pharmaceuticals, Inc. (ZYNE) have been reported on SEC Form 4 in the past 12 months.
Latest ZYNE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 13, 2023 | Terri B Sebree | President | Sell | $16K (12,401 @ $1.33) |
| Sep 13, 2023 | Armando Anido | Chairman & Chief Exec. Officer | Sell | $24K (17,830 @ $1.33) |
| Sep 13, 2023 | Kenneth T Jones | See Remarks | Sell | $3K (2,505 @ $1.33) |
| Sep 13, 2023 | Brian Rosenberger | VP, Commercial & Business Dev. | Sell | $8K (6,411 @ $1.33) |
| Sep 13, 2023 | James E Fickenscher | Chief Financial Officer | Sell | $12K (8,998 @ $1.33) |
| Jun 14, 2023 | Warren D Cooper | Director | Sell | $40 (115 @ $0.35) |
| Jun 14, 2023 | Kenneth I Moch | Director | Sell | $40 (115 @ $0.35) |
| Jun 14, 2023 | Pamela Stephenson | Director | Sell | $40 (115 @ $0.35) |
| Jun 14, 2023 | Daniel L Kisner | Director | Sell | $40 (115 @ $0.35) |
| Jun 14, 2023 | John P. Butler | Director | Sell | $40 (115 @ $0.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.